Ver­sant-backed Gotham Ther­a­peu­tics launch­es with $54M round and a new way to con­nect on mR­NA

New York has added an­oth­er biotech start­up to its grow­ing ros­ter for the Big Ap­ple hub.

The com­pa­ny is Gotham Ther­a­peu­tics, which now has a $54 mil­lion launch round to back its work on a plat­form built on the in­sights gleaned by Samie Jaf­frey, an in­ves­ti­ga­tor at the Weill Med­ical Col­lege of Cor­nell Uni­ver­si­ty who has spe­cial­ized in post-tran­scrip­tion­al mR­NA mod­i­fi­ca­tions.


The goal at Gotham is to cre­ate new drugs that can drug key pro­teins which mod­u­late mes­sen­ger RNA, with po­ten­tial­ly a big im­pact on a slate of dis­eases. Can­cer is an ear­ly fo­cus at the ear­ly-stage com­pa­ny, along with au­toim­mune dis­eases as well as a run at neu­ro­sciences, but CEO Lee Babiss is re­luc­tant to go in­to much de­tail about the specifics of their work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.